Aetna · Tirzepatide · US health-plan appeal rights

Tirzepatide denied as duplicate or overlapping therapy by Aetna?

Q: How long do I have to appeal a Aetna Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Aetna typically requires

HbA1c ≥6.5% per CVS Caremark form 5496-C.

Source policy: Aetna tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Aetna angle on Tirzepatide

# Aetna Tirzepatide Denials for Duplicate Therapy: Decoding the CVS Caremark Edit

Aetna's "duplicate therapy" denial on tirzepatide (Mounjaro for T2DM, Zepbound for obesity) is not a clinical judgment — it is a CVS Caremark RxClaim concurrent drug utilization review (cDUR) edit firing at point-of-sale when the patient's claims history shows an overlapping GLP-1 receptor agonist, dual GIP/GLP-1, or in some plan designs an SGLT2 or DPP-4 fill within the lookback window (typically 30–90 days). The denial appears on the EOB as reject code 88 (DUR Reject Error) with submission clarification opportunities, and is governed by Aetna Clinical Policy Bulletin (CPB) 0070 (Obesity) and the CVS Caremark Standard Formulary Prior Authorization Form 5496-C for tirzepatide in T2DM, which requires HbA1c ≥6.5% but is silent on whether tirzepatide may co-exist with a residual semaglutide/dulaglutide claim during cross-titration.

## Why the edit fires when it shouldn't

The most common false-positive scenarios are: (1) cross-titration from semaglutide or dulaglutide to tirzepatide, where the prior agent's last fill has not yet exhausted day's supply; (2) pen-vs-vial overlap during the 2025 compounded-tirzepatide wind-down following the FDA's resolution of the shortage; (3) Zepbound + Mounjaro both on file because the patient transitioned indications; and (4) legitimate combination therapy with metformin or an SGLT2 that the cDUR table misclassifies as duplicative. Caremark's edit treats any two incretin-class fills as duplicative regardless of overlap rationale — the prescriber must override via the Caremark Coverage Determination line (1-855-240-0536) with a DUR PPS code of "03" (Therapeutic Duplication — Prescriber Consulted) plus a written attestation that the prior agent is being discontinued.

## The procedural lever

Under 29 CFR §2560.503-1(g), Aetna's denial notice must identify the specific clinical rule and the records reviewed; a bare "duplicate therapy" rejection is facially noncompliant and grounds for an expedited internal appeal. For ERISA plans, invoke Pinto v. Aetna Life Ins. Co. (10th Cir. 2014) — Aetna bears the burden of substantiating its utilization-management determination, not the member. Push a Level 1 appeal through Aetna's Pharmacy Appeals unit (PO Box 14579, Lexington KY) with: (a) chart note documenting discontinuation date of the prior GLP-1; (b) HbA1c lab confirming ≥6.5% per Form 5496-C; (c) a signed prescriber statement that the regimens are sequential, not concurrent. If the plan is fully-insured, parallel-file with the state DOI — Texas, Florida, and California DOIs reverse Caremark cDUR denials at high rates when the prescriber attestation is unambiguous.

Tactical tip: Ask the prescriber to submit a fresh e-prescription with SIG note "Discontinue prior GLP-1 effective [date]; initiate tirzepatide" — this writes a discrete event to the Caremark claims engine that often clears the cDUR edit on resubmission within 24 hours, bypassing the appeal entirely.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Aetna appeals

Other insurers on Tirzepatide

Other denial reasons for Aetna Tirzepatide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.